Abstract: The present disclosure relates to adapter assemblies for use with and to electrically and mechanically interconnect electromechanical surgical devices and surgical reloads, and to surgical systems including handheld electromechanical surgical devices and adapter assemblies for connecting surgical reloads to the handheld electromechanical surgical devices.

Abstract: In an aspect a computer-implemented method is described. The method may include: causing a point-of-sale terminal processing a transaction to display a machine-readable code, the machine-readable code encoding a web address; receiving a request from a device that scanned the machine-readable code, the request received at the web address and the request including data; determining, based on data encoded in the machine-readable code and data included in the request, that the transaction may be processed using a value-added service; and in response to determining that the transaction may be processed using the value-added service, enabling completion of the transaction using the value-added service.

Abstract: The present disclosure relates to adapter assemblies for use with and to electrically and mechanically interconnect electromechanical surgical devices and surgical reloads, and to surgical systems including handheld electromechanical surgical devices and adapter assemblies for connecting surgical reloads to the handheld electromechanical surgical devices.

Abstract: A composition configured for oral use is provided, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.

Abstract: The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about ?10 mV. Further provided are processes for preparing such nanoemulsions.

Abstract: Meltable compositions configured for oral use, the compositions including at least one cannabinoid or cannabimimetic, are provided. The compositions include one or more fillers, typically a sugar alcohol, and a lipid. A method of forming such compositions is also provided.

Abstract: A wiring harness for a battery and inverter system includes a main cable. It further includes an inverter connector configured to plug the main cable into an inverter module. It further includes a first spur of the main cable terminating in a first-type battery device connector. It further includes a second spur of the main cable terminating in a second type battery device connector.

Abstract: The present disclosure relates to medicament injection devices. An injection device includes: a movable dosage programming component comprising a rotary encoder system having a predefined angular periodicity, a sensor arrangement including a first optical sensor configured to detect movement of the movable dosage programming component relative to the sensor arrangement during dosing of a medicament, wherein the first optical sensor is configured to operate in a strobe-sampling mode at a first frequency, a second optical sensor configured to detect movement of the rotary encoder system relative to the second optical sensor wherein the second optical sensor is configured to operate in a strobe-sampling mode at a second frequency lower than the first frequency, and a processor arrangement configured to, based on the detected movement, determine a medicament dosage administered by the injection device.

Abstract: A patient interface for delivery of a supply of pressurised air or breathable gas to an entrance of a patient's airways comprising: a cushion member that includes a retaining structure and a seal-forming structure permanently connected to the retaining structure; a frame member attachable to the retaining structure; and a positioning and stabilising structure attachable to the frame member.

Abstract: The invention relates to a method for sterilising an interior of a packaging, wherein the packaging has an upper film and a lower part, wherein the upper film and the lower part, in the closed state of the packaging, delimit the interior at least in some regions, wherein a sterilising substance is applied to a first surface of the upper film, wherein the sterilising substance contains iodine, wherein the upper film is arranged on the lower part in such a way that the first surface of the upper film faces the interior of the packaging at least in some regions, wherein the sterilising substance is arranged within the packaging and is activated from outside for a predetermined activation time period, and wherein an initial germ load within the packaging, in particular in the interior of the packaging, is preferably reduced by a factor of at least 106.

Abstract: The disclosure describes methods for the purification of protein-enriched extracts to provide concentrates and isolates and methods for incorporation of such materials into products. The purification methods are adapted for removal of one or more of ash, metal salts, alkaloids, particulates, heavy metals, and other impurities and/or contaminants from extracts, as well as modifying the sensory characteristics (e.g., odor, color, and/or taste characteristics) of extracts. The methods generally include diafiltration, treatment with functionalized resins, and supercritical extraction. A protein composition in the form of a concentrate or isolate is provided, the protein composition including RuBisCO, F2 fraction proteins, or combination thereof extracted from a plant of the Nicotiana species, wherein the protein composition is characterized by one or more of: an ash content of less than about 15% by weight; a nicotine content of less than about 10 ?g/g, and a heavy metal content of less than about 60 ?g/g.

Abstract: The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about ?10 mV. Further provided are processes for preparing such nanoemulsions.

Abstract: The disclosure provides a composition configured for oral use, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.

Abstract: The disclosure provides products configured for oral use, the products including compositions comprising a filler component including negatively charged groups and an active ingredient including positively charged groups. The active ingredient can be retained by the filler component at least in part through bonding between the negatively charged groups and the positively charged groups such that active ingredient may be release from the product when positioned within an oral cavity of a consumer.

Abstract: Meltable compositions configured for oral use, the compositions including at least one cannabinoid or cannabimimetic, are provided. The compositions include one or more fillers, typically a sugar alcohol, and a lipid. A method of forming such compositions is also provided.

Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

Abstract: The disclosure provides for solid products configured for oral use, the products including a carrier material; a releasable material; and wherein the releasable material is combined with the carrier material such that the releasable material is configured for sustained release from the solid product when the solid product is positioned in an oral cavity for a consumer. In another aspect, the disclosure provides for a method of preparing a solid product for oral use, the method comprising providing a releasable material in sprayable form; providing a pouch formed of a fibrous material; and spraying a flavor component onto a least a portion of the pouch one or both of before and after filling the pouch with the oral composition.

Abstract: The disclosure provides products configured for oral use, the products including compositions comprising a filler component including negatively charged groups and an active ingredient including positively charged groups. The active ingredient can be retained by the filler component at least in part through bonding between the negatively charged groups and the positively charged groups such that active ingredient may be release from the product when positioned within an oral cavity of a consumer.

Abstract: There is provided a client device arranged to receive a live adaptive bitrate stream, the client device further arranged to: request a manifest file; and request a manifest update hint. The client device further arranged to receive a manifest update hint, the manifest update hint including an indication of when the manifest will be updated; and request an updated manifest file at a time indicated by the manifest update hint.

Abstract: The disclosure provides products configured for oral use, the products including one or more agents adapted to or configured to reduce irritation that may be associated with release of a component from the products. Xylitol in particular may be useful as an irritation reducing agent. The disclosure further provides methods of reducing irritation associated with the release of one or more components from an oral composition or product.